Search

Your search keyword '"Barnes, Joanne"' showing total 383 results
Start Over Author "Barnes, Joanne"
383 results on '"Barnes, Joanne"'

1. Ashwagandha

Author

Lim, Xin Yi and Barnes, Joanne

Published
2024

2. Ganoderma lucidum

Author

Milosavljevic, Aleksandra and Barnes, Joanne

Published
2023

3. Pine bark

Author

Lee, E. Lyn and Barnes, Joanne

Published
2023

4. Garcinia

Author

Milosavljevic, Aleksandra and Barnes, Joanne

Published
2023

6. Saffron

Author

Barnes, Joanne

Published
2022

16. Ginkgo

Author

Barnes, Joanne

Published
2010

34. An examination of the role of the pharmacist in the safe, effective and appropriate use of complementary medicines

Author

Barnes, Joanne

Subjects
615.5, Pharmacognosy
Abstract

In the UK, complementary medicines (CMs), including herbal and homoeopathic products, are used extensively and increasingly by patients and the public. This pervasive use of CMs raises concerns related to patient safety which suggest that there is a public need for a health-care provider who can advise on and monitor their safe, effective and appropriate use. The aim of this thesis is to investigate, from both the users' and the pharmacists' perspectives, the potential of the pharmacist to take on such a role. The present work confirms the need for an expert adviser-monitor on CMs, and shows that pharmacists have the potential to undertake this function. Data resulting from the work show that most pharmacies sell CMs, and that users of CMs and pharmacists interact with respect to the use of these types of products. Therefore, there are opportunities for pharmacists to advise patients and the public on the safe, effective and appropriate use of CMs. Furthermore, there are ways in which pharmacists can contribute to increasing the evidence base for CMs, not only by collating current knowledge, but also by conducting community-pharmacy-based clinical research projects. However, the data raise several concerns, such as the extent of pharmacists' knowledge and training, and their professional practice regarding CMs. Pharmacists and the profession need to address these issues. Consequently, it is recommended that pharmacognosy (the study of natural products used in medicine) and areas of complementary/alternative medicine (CAM), particularly CMs, be included on the indicative syllabus for Master of Pharmacy (MPharm) degree programmes. Also, the training needs of practising pharmacists in these areas should be reviewed. Pharmacists should be encouraged to improve their professional practice pertaining to CMs, including reporting adverse drug reactions for herbal products. There is a corresponding need to raise public awareness of the pharmacist as a source of objective, reliable advice and information on CMs. In addition, an ongoing programme of research is suggested to clarify the area of CAM within pharmacy, and to determine the implications of CAM use for pharmaceutical care.

Published
2001

35. Ashwagandha.

Author

Xin Yi Lim and Barnes, Joanne

Subjects
ANXIETY prevention, FERTILITY, MEDICINAL plants, PSYCHOLOGICAL stress, PHYSICAL fitness, BODY movement
Abstract

The article focuses on the medicinal properties and safety concerns of ashwagandha, a widely used herb in Ayurvedic medicine, highlighting its potential benefits and risks. Topics discussed include its traditional uses, preparations, marketed claims such as adaptogenic properties, and evidence from preclinical and clinical studies supporting its efficacy in various conditions like anxiety and infertility, along with safety issues like liver toxicity and interactions with other medications.

Published
2024
Full Text
View/download PDF

40. Guidelines for Submitting Adverse Event Reports for Publication

Author

Kelly, William, Arellano, Felix, Barnes, Joanne, Bergman, Ulf, Edwards, Ralph, Fernandez, Alina, Freedman, Stephen, Goldsmith, David, Huang, Kui, Jones, Judith, McLeay, Rachel, Moore, Nicholas, Stather, Rosie, Trenque, Thierry, Troutman, William, van Puijenbroek, Eugène, Williams, Frank, and Wise, Robert

Published
2009
Full Text
View/download PDF

46. Guidelines for Submitting Adverse Event Reports for Publication

Author

Kelly, William N., Arellano, Felix M., Barnes, Joanne, Bergman, Ulf, Edwards, Ralph I., Fernandez, Alina M., Freedman, Stephen B., Goldsmith, David I., Huang, Kui A., Jones, Judith K., McLeay, Rachel, Moore, Nicholas, Stather, Rosie H., Trenque, Thierry, Troutman, William G., van Puijenbroek, Eugene, Williams, Frank, and Wise, Robert P.

Published
2007
Full Text
View/download PDF

47. Cytisine versus varenicline for smoking cessation for Māori (the indigenous people of New Zealand) and their extended family: protocol for a randomized non‐inferiority trial

Author

Walker, Natalie, Smith, Barry, Barnes, Joanne, Verbiest, Marjolein, Kurdziel, Tomasz, Parag, Varsha, Pokhrel, Subhash, Bullen, Chris, Ouderen, and Tranzo, Scientific center for care and wellbeing

Subjects
Cytisine, Counseling, Native Hawaiian or Other Pacific Islander, STRATEGIES, safety trial, NONINFERIORITY, effectiveness, Equivalence Trials as Topic, Trial Protocol, COST-EFFECTIVENESS, Alkaloids, NICOTINE, DRUGS, Humans, Family, indigenous, Randomized Controlled Trials as Topic, Smoking Cessation Agents, non-inferiority, FAGERSTROM TEST, Carbon Dioxide, EFFICACY, Azocines, varenicline, non‐inferiority, SAFETY, randomized, RECEPTOR PARTIAL AGONIST, Smoking Cessation, Patient Safety, EXTENSION, Quinolizines, New Zealand
Abstract

Background and aims Cytisine, a nicotinic acetylcholine receptor partial agonist (like varenicline) found in some plants, is a low‐cost, effective smoking cessation medication that may appeal to Māori [the indigenous people of New Zealand (NZ)]. The RAUORA trial aims to determine the effectiveness, safety and cost‐effectiveness of cytisine (Tabex®) versus varenicline (Champix®) for smoking cessation in Māori and the whānau (extended family) of Māori. Design Pragmatic, community‐based, open‐label randomized non‐inferiority trial. Setting Lakes District Health Board region, NZ. Participants Daily smokers (n = 2140) who self‐identify as Māori or whānau of Māori, and are: aged ≥ 18 years, motivated to quit smoking in the next 2 weeks, eligible for subsidized varenicline, able to provide verbal consent and have daily access to a mobile phone/internet. Recruitment uses multi‐media advertising. Intervention and comparator Participants are randomized (1 : 1 ratio) to receive a prescription for 12 weeks of cytisine tablets [following the manufacturer's dosing regimen for 25 days, then one 1.5‐mg tablet every 6 hours (two per day) until 12 weeks] or varenicline tablets (following the manufacturer's dosing regimen). Both groups receive brief stop‐smoking advice from the prescribing doctor and withdrawal‐orientated behavioural support via community‐based stop‐smoking counselling services (frequency, duration and mode of delivery tailored for participants) or a research assistant (six weekly 10–15‐minute calls). Participants are advised to reduce their smoking over the first 4 days of treatment, with day 5 as their designated quit‐date. Measurements The primary outcome is carbon monoxide‐verified continuous abstinence at 6 months post‐quit date. Secondary outcomes at 1, 3, 6 and 12 months post‐quit date include: self‐reported continuous abstinence, 7‐day point prevalence abstinence, cigarettes per day, time to (re)lapse, adverse events, treatment adherence/compliance, treatment acceptability, nicotine withdrawal/urge to smoke and health‐care utilization/health‐related quality of life. Comments This trial compares cytisine and varenicline when used by the indigenous people of NZ and their extended family for smoking cessation.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results